Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Jazz Pharmaceuticals executive Samantha Pearce, EVP and Chief Commercial Officer, reported that 780 Ordinary Shares were withheld on 2026-08-05 at $261.62 per share to satisfy tax obligations from vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 47,131 Ordinary Shares.
Winningham Rick E reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Rick E Winningham reported an equity award of 1,605 restricted stock units, each representing one ordinary share, granted at $0.0000 per share under the 2007 Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 11,172 ordinary shares.
LOVE TED W reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Ted W. Love received a grant of 1,605 restricted stock units, each representing a contingent right to receive one ordinary share at a cash price of $0.00 per share.
The award was granted under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to his continuous service and other conditions. Following this grant, Love directly holds 3,132 ordinary shares.
Hamill Laura reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc reported that director Laura Hamill received a grant of 1,605 restricted stock units, each representing one ordinary share, for no cash consideration. These units vest in full on July 23, 2027, subject to continuous service, bringing her direct holdings to 8,538 ordinary shares.
Kennedy Patrick reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick Kennedy reported a grant of 1,605 restricted stock units, each representing one ordinary share, under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his direct holdings to 8,307 ordinary shares.
Smith Mark Douglas reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Mark Douglas Smith reported an equity compensation grant of 1,605 restricted stock units, each representing a right to receive one ordinary share. The award was made at $0.0000 per share under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and other conditions. Following this grant, Smith directly holds 11,285 ordinary shares.
Cook Jennifer E. reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 1,605 restricted stock units, each representing one ordinary share, at a reported price of $0.0000 per share. Granted under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan, the units vest in full on July 23, 2027, subject to continuous service and conditions. Following this award, she directly holds 12,442 ordinary shares.
Mulligan Seamus reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Seamus Mulligan received an equity award covering 1,605 ordinary shares through restricted stock units under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. The units vest in full on July 23, 2027, subject to continuous service and conditions. After this award he holds 1,184,633 ordinary shares directly, plus 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by him and his immediate family.
McSharry Heather Ann reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Heather Ann McSharry received a grant of 1,605 restricted stock units representing contingent rights to ordinary shares. The award was issued under the company’s 2007 Amended and Restated Non-Employee Directors Stock Award Plan and will vest in full on July 23, 2027, subject to continuous service and certain conditions. Following this grant, McSharry is reported to hold 20,054 ordinary shares directly.
ENRIGHT PATRICK G reported acquisition or exercise transactions in this Form 4 filing.
Jazz Pharmaceuticals director Patrick G. Enright received a grant of 1,605 restricted stock units, each representing a contingent right to one ordinary share upon vesting, under the 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to continuous service and conditions, the units vest in full on July 23, 2027, bringing his reported holdings for this security to 22,984 shares.